HopeStage
Back to overview

ADHD studies

Topics
More filters

ADHD

Attention-deficit/hyperactivity disorder (ADHD) involves persistent difficulties with attention, impulsivity or restlessness that can affect everyday life.

1811studies shown
Showing 997-1,008 of 1,811
Drug study icon
CompletedNCT00191880

Study of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder

Official study title

A Phase IIIb Open-Label Trial of Atomoxetine Hydrochloride to Evaluate Academic Outcome in Children Ages 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder

This study has finished and is no longer accepting participants.

Multiple locations, including Calgary
ADHDMedication studyAges 8–11
Countries
Canada
Sponsor
Eli Lilly and Company
Drug study icon
CompletedNCT02215538

OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD

Official study title

Concerta in the Treatment of Adult ADHD and a Comparison of Four Adult ADHD Scales and Effects on Personality

This study has finished and is no longer accepting participants.

In Salt Lake City
ADHDMedication studyAges 18–65
Countries
United States
Sponsor
University of Utah
Behavioral study icon
CompletedNCT03957993

OT Intervention Via Telehealth for Children With ASD and ADHD

Official study title

Pilot Study: Addressing Home-Based Functional Challenges Via Telehealth-Based Occupational Therapy

This study has finished and is no longer accepting participants.

In Cincinnati
ADHDInterventional studyAges 4–18
Countries
United States
Sponsor
Children's Hospital Medical Center, Cincinnati
Drug study icon
CompletedNCT01907360

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

Official study title

A Phase I/II, Single Center, Single-Treatment, Open-Label, Adaptive Clinical Trial Design Examining the Pharmacokinetic Effects of up to Two Separate HLD200 Modified Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects With ADHD

This study has finished and is no longer accepting participants.

In Las Vegas
ADHDMedication studyAges 6–17
Countries
United States
Sponsor
Ironshore Pharmaceuticals and Development, Inc
Drug study icon
CompletedNCT02286817

NFC-1 for ADHD

What is this study about?

This study evaluated the safety and effectiveness of NFC-1 for people with ADHD.

This study has finished and is no longer accepting participants.

In Philadelphia
ADHDMedication studyAges 12–17
Countries
United States
Sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Drug study icon
CompletedNCT00573534

Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse

Official study title

Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence

This study has finished and is no longer accepting participants.

Location not clearly listed
ADHDMedication studyAges 11–15
Countries
Sponsor
New York State Psychiatric Institute
Other study type icon
TerminatedNCT03942835

Psychometric Validation of the Competitive Attention Test

Official study title

Psychometric Validation of the Competitive Attention Test (CAT) : Simultaneous and Separated Measures of Voluntary and Involuntary Attention

This study ended early.

In Bron
ADHDInterventional studyAges 6–90
Countries
France
Sponsor
Hospices Civils de Lyon
Other study type icon
CompletedNCT02217371

Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in adults with Attention Deficit Disorder With or Without Hyperactivity

Official study title

Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity

This study has finished and is no longer accepting participants.

In Bordeaux
ADHDInterventional studyAges 18–50
Countries
France
Sponsor
University Hospital, Bordeaux

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.